Publication|Articles|October 6, 2026

Pharmacy Times

  • October 2026
  • Volume 92
  • Issue 10

mRNA Reenters the Mainstream

Fact checked by: Yasmeen Qahwash

Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.

In early August this year, mFlusiva (mRNA-1010; Moderna) was approved as the first messenger RNA (mRNA) influenza vaccine, labeled for adults 50 years and older. Based on favorable immunogenicity findings against high-dose conventional vaccines, prescribers may also consider mFlusiva for patients 65 years and older instead of the high-dose vaccination. With a 26.6% relative vaccine efficacy compared with standard-dose therapy, mFlusiva may be a worthwhile option not only for patients with egg allergy concerns but also for the broader at-risk older population.1

Related to this article